Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.4 to v3.5.5, indicating a new version of the page content. This appears to be a metadata/software update that does not change the study details, eligibility, or results.
    Difference
    0.0%
    Check dated 2026-06-05T22:02:21.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.5.3 to v3.5.4. This indicates a new version of the page without changes to the study details.
    Difference
    0.0%
    Check dated 2026-05-15T15:01:03.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    A Publications section was added, listing a PubMed citation for Subcutaneous ocrelizumab in multiple sclerosis and noting that these publications are automatically filled from PubMed.
    Difference
    0.2%
    Check dated 2026-05-08T11:45:05.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page’s revision/version label has been updated from v3.5.2 to v3.5.3, reflecting a site software release rather than a change to the clinical trial record.
    Difference
    0.0%
    Check dated 2026-04-24T05:49:29.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:17:36.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 is reflected on the page.
    Difference
    0.0%
    Check dated 2026-03-19T04:55:39.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.